Overview
Inflammation of the bronchus caused by Aspergillus species, particularly Aspergillus fumigatus, represents a serious and potentially life-threatening condition often seen in immunocompromised patients. This entity can manifest as part of invasive pulmonary aspergillosis (IPA) or as a distinct entity like pulmonary mucormycosis, where Aspergillus involvement may coexist or be a primary pathogen. Clinical presentation can vary widely, from subtle respiratory symptoms to severe respiratory failure, depending on the patient's immune status and the extent of bronchial involvement. Early recognition and prompt intervention are crucial for improving outcomes, as delayed treatment can lead to significant morbidity and mortality.
Clinical Presentation
Patients with Aspergillus-induced bronchial inflammation typically present with a constellation of respiratory symptoms that can be nonspecific but often include fatigue, cough, and dyspnea. These symptoms may progress to more severe manifestations such as hypoxemia, reflecting the extent of airway obstruction and parenchymal involvement. Imaging studies, particularly computed tomography (CT) scans, often reveal characteristic findings such as endobronchial masses, bronchial wall thickening, and in severe cases, fistulae extending to adjacent structures like the mediastinum. These fistulae can indicate advanced disease and are more frequently observed in pulmonary mucormycosis compared to invasive pulmonary aspergillosis, as noted in a study where 67% of mucormycosis cases versus 27% of IPA cases exhibited such abnormalities [PMID:33719109].
Bronchoscopy plays a pivotal role in the clinical evaluation, offering direct visualization of endobronchial abnormalities. In a cohort of 107 subjects with suspected invasive mould infections, bronchoscopy contributed significantly to diagnosis in 71% of cases, highlighting its diagnostic utility [PMID:33719109]. Findings during bronchoscopy may include endobronchial masses, pseudomembranes, and the presence of fungal elements, which can be further confirmed through histopathological examination and culture. Specific symptoms and imaging findings should prompt consideration of other differential diagnoses, such as chronic obstructive pulmonary disease (COPD), malignancy, and other fungal infections like Candida or Cryptococcus, especially in immunocompromised hosts.
Diagnosis
Diagnosing Aspergillus-induced bronchial inflammation requires a multifaceted approach combining clinical suspicion, imaging, and direct visualization techniques. CT scans are foundational, often revealing characteristic patterns such as nodular infiltrates, cavitation, and bronchial wall thickening. However, definitive diagnosis typically hinges on bronchoscopic findings and microbiological confirmation. Bronchoscopy not only visualizes endobronchial masses and fistulae but also facilitates sampling for histopathological examination and culture. In one study, biopsy samples identified Aspergillus fumigatus as the causative agent, underscoring the importance of obtaining adequate tissue samples for accurate identification [PMID:25513736].
Laboratory tests, including galactomannan antigenemia and beta-D-glucan assays, can support the diagnosis, particularly in immunocompromised patients, though they lack specificity when used alone. These tests should be interpreted in conjunction with clinical and radiological findings. Additionally, molecular diagnostics, such as polymerase chain reaction (PCR) for Aspergillus DNA, offer rapid and sensitive detection but are not yet universally available. The integration of these diagnostic modalities helps in confirming the presence of Aspergillus and guiding appropriate antifungal therapy.
Management
The management of Aspergillus-induced bronchial inflammation primarily revolves around aggressive antifungal therapy tailored to the patient's immune status and the severity of the infection. All patients require systemic antifungal treatment, with Aspergillus fumigatus being a common target. Voriconazole remains the first-line therapy for invasive aspergillosis due to its broad efficacy and favorable pharmacokinetic profile. Recommended dosing typically starts with intravenous voriconazole at 6 mg/kg every 12 hours, transitioning to oral therapy at 200 mg twice daily once the patient is stable and tolerating oral intake [PMID:25513736]. For patients with refractory disease or intolerance to voriconazole, alternative agents such as isavuconazole, itraconazole, or echinocandins (e.g., micafungin, caspofungin) may be considered based on clinical guidelines and susceptibility testing.
In cases involving endobronchial involvement with significant obstruction or fistulae, adjunctive interventions may be necessary. Bronchoscopic debridement and stenting can alleviate airway obstruction and improve oxygenation. For instance, in a series of cases, bronchoscopic interventions contributed to healing of fistulae in two patients, although the overall prognosis was heavily influenced by underlying conditions such as leukemia [PMID:25513736]. Close monitoring of clinical status, including serial imaging and laboratory parameters (e.g., inflammatory markers, galactomannan levels), is essential to assess treatment response and detect potential complications early.
Monitoring and Follow-Up
Complications
Despite advances in diagnostic and therapeutic approaches, complications associated with Aspergillus bronchial inflammation can be severe and life-threatening. Major complications include but are not limited to respiratory failure, sepsis, and disseminated infection. Among 107 subjects in a recent study, major complications occurred in 2.7% of cases, with one fatality noted, underscoring the potential risks despite generally favorable procedural outcomes [PMID:33719109]. Bronchoscopy itself carries inherent risks, including bleeding, infection at the site of sampling, and transient hypoxemia, which must be carefully managed.
Prognosis is heavily influenced by the patient's underlying condition, the severity of the bronchial involvement, and the timeliness and appropriateness of antifungal therapy. Immunocompromised patients, particularly those with hematologic malignancies or those undergoing organ transplantation, face a higher risk of poor outcomes. Early intervention and multidisciplinary care, involving pulmonologists, infectious disease specialists, and hematologists, are critical in mitigating these risks and improving survival rates.
Key Recommendations
References
1 Muthu V, Gandra RR, Dhooria S, Sehgal IS, Prasad KT, Kaur H et al.. Role of flexible bronchoscopy in the diagnosis of invasive fungal infections. Mycoses 2021. link 2 Argento AC, Wolfe CR, Wahidi MM, Shofer SL, Mahmood K. Bronchomediastinal fistula caused by endobronchial aspergilloma. Annals of the American Thoracic Society 2015. link
2 papers cited of 3 indexed.